At a glance
- Originator Wyeth
- Class Anti-inflammatories; Antirheumatics; Benzonitrile; Small molecules
- Mechanism of Action Interleukin 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
Most Recent Events
- 15 Oct 2009 Pfizer acquires Wyeth
- 09 Sep 1998 No Development Reported for Rheumatoid arthritis in USA